[go: up one dir, main page]

CA2367375A1 - Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil - Google Patents

Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil Download PDF

Info

Publication number
CA2367375A1
CA2367375A1 CA002367375A CA2367375A CA2367375A1 CA 2367375 A1 CA2367375 A1 CA 2367375A1 CA 002367375 A CA002367375 A CA 002367375A CA 2367375 A CA2367375 A CA 2367375A CA 2367375 A1 CA2367375 A1 CA 2367375A1
Authority
CA
Canada
Prior art keywords
fgf
eye
gene delivery
vector
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002367375A
Other languages
English (en)
Inventor
William C. Manning, Jr.
Varavani J. Dwarki
Katherine Rendahl
Shang-Zhen Zhou
Laura H. Mcgee
Dana Lau
John G. Flannery
Sheldon Miller
Fei Wang
Adriana Di Polo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Novartis Vaccines and Diagnostics Inc
University of California San Diego UCSD
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2367375A1 publication Critical patent/CA2367375A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des vecteurs d'administration de gènes, tels que, par exemple, des vecteurs de virus associés aux adénovirus recombinants, ainsi que des techniques d'utilisation de tels vecteurs pour le traitement ou la prévention des maladies de l'oeil.
CA002367375A 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil Abandoned CA2367375A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12446099P 1999-03-15 1999-03-15
US60/124,460 1999-03-15
US17498400P 2000-01-06 2000-01-06
US60/174,984 2000-01-06
PCT/US2000/007062 WO2000054813A2 (fr) 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil

Publications (1)

Publication Number Publication Date
CA2367375A1 true CA2367375A1 (fr) 2000-09-21

Family

ID=26822618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002367375A Abandoned CA2367375A1 (fr) 1999-03-15 2000-03-15 Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil

Country Status (5)

Country Link
EP (1) EP1183051A2 (fr)
JP (1) JP2002539176A (fr)
AU (1) AU3755900A (fr)
CA (1) CA2367375A1 (fr)
WO (1) WO2000054813A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
JP2002542805A (ja) 1999-04-30 2002-12-17 ユニバーシティ オブ フロリダ アデノ随伴ウイルス送達リボザイム組成物および使用方法
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
US7408047B1 (en) 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU2008201780B2 (en) * 1999-09-07 2012-05-17 Amgen Inc. Fibroblast growth factor-like polypeptides
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
AU1101901A (en) * 1999-10-22 2001-05-08 Chiron Corporation Human fgf-20 gene and gene expression products
WO2001036640A2 (fr) * 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
JP2003522160A (ja) * 2000-02-11 2003-07-22 ジェンベク、インコーポレイティッド 眼関連疾患の治療のための遺伝子治療
WO2001068854A2 (fr) * 2000-03-13 2001-09-20 Amgen, Inc. Molecules s'apparentant au facteur de croissance des fibroblastes et leurs utilisations
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸
AU2001292881A1 (en) * 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
JP2004537267A (ja) * 2000-11-06 2004-12-16 キュラジェン コーポレイション 増殖因子を使用する炎症性腸疾患の処置
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
CN101732731B (zh) * 2000-12-19 2013-04-10 研究发展基金会 慢病毒载体介导的基因转移及其用途
CA2446285A1 (fr) * 2001-06-15 2002-12-27 Curagen Corporation Facteur de croissance fibroblastique (fgf) et acides nucleiques codant ce facteur
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
AU2003225910A1 (en) * 2002-03-20 2003-10-08 Johns Hopkins University Raav vector compositions and methods for the treatment of choroidal neovascularization
CA2483624A1 (fr) 2002-05-01 2004-04-01 University Of Florida Research Foundation, Inc. Systemes d'expression raav ameliores destines a une modification genetique de proteines de capside specifiques
JP2005218780A (ja) * 2004-02-09 2005-08-18 Menicon Co Ltd 薬物放出速度を制御し得る薬物徐放可能なヒドロゲル材料の製造方法
WO2006031689A2 (fr) 2004-09-13 2006-03-23 Genzyme Corporation Complexes multimeriques
EP2099468B1 (fr) * 2006-12-05 2018-07-11 The Royal Institution for the Advancement of Learning/McGill University Procédés d'utilisation de modulateurs de récepteur trk
JP2011511090A (ja) * 2008-02-07 2011-04-07 セレジーン インコーポレイテッド 治療用タンパク質をコードする発現ベクターの硝子体内投与による光受容体のレスキュー方法
WO2010011404A2 (fr) 2008-05-20 2010-01-28 Eos Neuroscience, Inc. Vecteurs pour la délivrance de protéines photosensibles et procédés d’utilisation
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
CA2760674A1 (fr) 2009-05-05 2010-11-11 Amgen Inc. Mutants de fgf21 et leurs utilisations
RS65153B1 (sr) 2009-05-05 2024-02-29 Amgen Inc Fgf21 mutanti i njihove upotrebe
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN101947309B (zh) * 2010-04-12 2012-09-19 南海朗肽制药有限公司 人碱性成纤维细胞生长因子滴眼液及其制备方法
CA2796055A1 (fr) 2010-04-15 2011-10-20 Amgen Inc. Proteines de liaison au recepteur de fgf humain et a ?-klotho
EP2601214B1 (fr) 2010-08-06 2017-11-01 Genzyme Corporation Compositions d'antagonistes de vegf et leurs applications
TWI702955B (zh) * 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
CA2942324C (fr) 2014-03-11 2024-05-14 Wayne State University Promoteur mglur6 modifie et procedes d'utilisation
ES3042252T3 (en) 2014-03-17 2025-11-19 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
BR112017018846A2 (pt) 2015-03-02 2018-07-31 Adverum Biotechnologies, Inc. composições e métodos para entrega intravítrea de polinucleotídeos a cones retinianos.
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2718150B1 (fr) * 1994-03-29 1996-04-26 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
DE69736860T2 (de) * 1996-09-24 2007-05-16 Merck & Co., Inc. Verbindungen zur hemmung der angiogenese durch gentherapie
EP1173191A4 (fr) * 1997-05-13 2004-12-01 Univ California Nouveaux agents peptidiques anti-angiogeniques, utilisation de ces derniers pour la therapie et le diagnostic
JPH11100327A (ja) * 1997-09-26 1999-04-13 Toray Ind Inc 網膜変性症治療剤
AU9673998A (en) * 1997-10-01 1999-04-23 G.D. Searle & Co. Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment
WO1999045952A2 (fr) * 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
CA2346262A1 (fr) * 1998-09-17 2000-03-23 University Of Florida Methodes de traitement de maladies degeneratives de la retine

Also Published As

Publication number Publication date
WO2000054813A3 (fr) 2001-05-03
JP2002539176A (ja) 2002-11-19
EP1183051A2 (fr) 2002-03-06
WO2000054813A2 (fr) 2000-09-21
AU3755900A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
US6943153B1 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
CA2367375A1 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prevention des maladies de l'oeil
WO2002024234A2 (fr) Utilisation de vecteurs recombines d'administration genique pour traiter ou prevenir des maladies de l'oeil
CA2873628C (fr) Traitement de la dmla en utilisant aav sflt-1
Bennett et al. Adenovirus-mediated delivery of rhodopsin-promoted bcl-2 results in a delay in photoreceptor cell death in the rd/rd mouse
EP1311699B1 (fr) Distribution de facteurs angiogeniques a mediation assuree par virus associe aux adenovirus
US6106826A (en) Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
US20030129164A1 (en) Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
Jomary et al. Adenovirus‐mediated gene transfer to murine retinal cells in vitro and in vivo
Bainbridge et al. Gene therapy for ocular angiogenesis
US20100172871A1 (en) Muller Cell Specific Gene Therapy
Dijkhuizen et al. Adenoviral vector‐directed expression of neurotrophin‐3 in rat dorsal root ganglion explants results in a robust neurite outgrowth response
JP2011516049A (ja) 遺伝子障害を治療する方法
CA2410512A1 (fr) Compositions a base de vecteur viral associe a l'adenovirus et leurs utilisations therapeutiques
JP4689144B2 (ja) 眼球血管新生を処置するための方法
US20100184838A1 (en) Compositions and methods for retinal transduction and photoreceptor specific transgene expression
US7037493B2 (en) Method of inducing neuronal production in the brain and spinal cord
US20040116343A1 (en) Nucleic acid constructs cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension
KR20040108804A (ko) 우두 ａｔｉ 프로모터를 사용하는 것에 의한 변형백시니아 바이러스 안카라에서 유전자의 발현
IL321968A (en) Recombinant adeno-associated virus vector
US20060122112A1 (en) Method for preventing or treating osteosarcoma
JP2006516112A (ja) 眼の遺伝子治療
HK40010151A (en) Treatment of amd using aav sflt-1
HK40010151B (en) Treatment of amd using aav sflt-1
HK1207568B (en) Treatment of amd using aav sflt-1

Legal Events

Date Code Title Description
FZDE Discontinued